经中国证券监督管理委员会《关于同意甘李药业股份有限公司向特定对象发 行股票注册的批复》（证监许可［2023］1284 号）核准，并经上海证券交易所同 意，公司于 2023 年 11 月 27 日向特定对象发行股票 28,508,550 股，每股发行价 格为 27.12 元，募集资金总额为 773,151,876.00 元，扣除各类发行费用之后实际 1 中信证券股份有限公司 关于甘李药业股份有限公司向特定对象发行 A 股股票 之持续督导保荐总结报告书 | | | 一、发行人基本情况 | 情况 | | | | | | | | | 内容 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 发行人名称 | 甘李药业股份有限公司 | | | | | | | | | | | | | | | | | 证券代码 | 603087.SH | | | | | | | | | | | | | | | | | 注册资本 | 万元 60106.5 ...

Core Points - Gannee Pharmaceutical (甘李药业) announced the completion of a share reduction plan by its shareholder, Beijing Xutong Hongda Technology Co., Ltd. (旭特宏达), which reduced its holdings by 6,010,622 shares, representing 1% of the company's total share capital [1][2] - The share reduction occurred between April 22, 2025, and April 30, 2025, with a price range of 44.85 to 49.81 yuan per share, totaling approximately 290.35 million yuan [1][2] - After the reduction, Xutong Hongda holds 35,473,235 shares, accounting for 5.90% of the total share capital [2] Shareholder Information - Before the reduction, Xutong Hongda and its concerted party, Gan Zhongru, held a combined total of 247,127,614 shares, which is 41.11% of the total share capital [3] - Xutong Hongda owned 41,483,857 shares (6.90%), while Gan Zhongru held 205,643,757 shares (34.21%) [3] - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, and Xutong Hongda is the second largest [3] Fundraising Activities - Gannee Pharmaceutical went public on June 29, 2020, raising a total of 2.545 billion yuan, with a net amount of 2.441 billion yuan after expenses [4] - The funds raised were allocated for various projects, including marketing network construction and product registration in the U.S. [4] - In 2023, the company issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [5]

Group 1 - Major shareholders of *ST WanFang plan to reduce their holdings by up to 9,341,596 shares, accounting for 3% of the company's total share capital from May 27 to August 25, 2025 [1] - Shareholders of Airo Energy intend to reduce their holdings by up to 800,000 shares, 800,000 shares, and 1,600,000 shares, representing 0.50%, 0.50%, and 1% of the company's total share capital respectively during the same period [1] - Anner plans to reduce its holdings by up to 3,186,159 shares, which is 1.5% of the company's total share capital, from May 27 to August 26, 2025 [1] Group 2 - Shareholders of Chuhuan Technology plan to reduce their holdings by up to 2,395,605 shares, accounting for 3% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [1] - Major shareholder of Dalian Technology intends to reduce their holdings by up to 4,189,336 shares, which is 0.99% of the company's total share capital from May 27 to August 26, 2025 [2] - Dongwei Technology's board members plan to reduce their holdings by a total of 2,574,857 shares, representing 0.8629% of the company's total share capital during the same period [2] Group 3 - Gann Li Pharmaceutical's shareholder has completed a reduction of 6,010,622 shares, which is 1% of the company's total share capital from April 22 to April 30, 2025 [2] - Guanshi Technology's board members plan to reduce their holdings by up to 359,375 shares, accounting for 0.4891% of the company's total share capital from May 27 to August 26, 2025 [2] - Guoguang Electric's shareholder has completed a reduction of 1,625,751 shares, which is 1.5% of the company's total share capital from April 25 to April 30, 2025 [2] Group 4 - Haili Biological's major shareholder has completed a reduction of 13,113,244 shares, representing 2% of the company's total share capital from April 15 to April 22, 2025 [3] - Hengfeng Information's board member has completed a reduction of 198,717 shares, which is 0.1207% of the company's total share capital on April 28, 2025 [3] - Hongwei Technology's shareholder plans to reduce their holdings by up to 820,000 shares, accounting for 0.39% of the company's total share capital from May 12 to August 11, 2025 [3] Group 5 - Huatai Medical's vice president has completed a reduction of 29,943 shares, which is 0.0308% of the company's total share capital from April 28 to April 29, 2025 [4] - Jilin Carbon Valley's major shareholder has completed a reduction of 4,989,160 shares, representing 0.8490% of the company's total share capital from April 25 to April 29, 2025 [4] - Jiahua Technology's shareholder plans to reduce their holdings by up to 1,160,000 shares, accounting for 1.50% of the company's total share capital from May 28 to August 25, 2025 [4] Group 6 - Jiangbo Long's shareholder plans to reduce their holdings by up to 4,159,815 shares, which is 1% of the company's total share capital from May 27 to August 26, 2025 [5] - Jiangshan Co. plans to reduce its holdings in Jiangtian Chemical by 4,330,800 shares, accounting for 3% of its total share capital from May 27 to August 26, 2025 [5] - Kairun Co.'s major shareholder plans to reduce their holdings by up to 9,000,000 shares, representing 2.43% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [5] Group 7 - Lianqi Technology's shareholders plan to reduce their holdings by a total of 18,717,374 shares, which is 2.96% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [9] - Zhongke Information's board members have completed a reduction of 698,914 shares, representing 0.2358% of the company's total share capital [9] - Zhongshi Co.'s major shareholder plans to reduce their holdings by up to 1,800,000 shares, accounting for 1.1527% of the company's total share capital from May 27 to August 26, 2025 [10]

证券代码：603087 证券简称：甘李药业 公告编号：2025-028 甘李药业股份有限公司 关于公司控股股东及实际控制人 部分股份解押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 甘李药业股份有限公司（以下简称"公司"）控股股东及实际控制人甘忠如先生持有公司股份 205,643,757股，占公司总股本的34.21%。2025年4月29日公司收到通知，甘忠如先生已于近日办理完毕 14,000,000股公司股份的解押登记手续。 ● 控股股东、实际控制人甘忠如先生及其控制的北京旭特宏达科技有限公司（以下称"旭特宏达"）合计 持有公司股份246,277,792股，占公司总股本的40.97%。本次股份解除质押后，甘忠如先生及旭特宏达 累计质押公司股份数量为38,220,000股，占其持股数量的15.52%，占公司总股本的6.36%。 一、本次股份质押解除情况 ■ 二、股东累计质押股份情况 2025年4月30日 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： ■ 注：目前处于旭特宏达减持计划实 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-029 甘李药业股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、减持主体减持前基本情况 | 股东名称 | 旭特宏达 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | √是 □否 | | | 直接持股 5%以上股东 | √是 □否 | | | 董事、监事和高级管理人员 | □是 √否 | | | 其他：无 | | | 持股数量 | 41,483,857股 | | 1 大股东持股的基本情况：本次减持计划实施前，北京旭特宏达科技有限公司 （以下简称"旭特宏达"）及其一致行动人甘忠如先生合计持有甘李药业股 份有限公司（以下简称"公司"）247,127,614 股，占公司总股本的 41.11%。 其中旭特宏达持有公司股份 41,483,857 股，占公司总股本的 6.90%。甘忠如 先生持有公司股份 205,643,757 股，占公司总股本的 34.21%。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、本次股份质押解除情况 | 股东名称 | 甘忠如 | | | | | --- | --- | --- | --- | --- | | 本次解除质押股份 | 14,000,000 | | | 股 | | 占其所持股份比例 | 6.81% | | | | | 占公司总股本比例 | 2.33% | | | | | 解除质押/冻结/标记时间 | 年 2025 4 | 月 | 日 28 | | | 直接持股数量 | 205,643,757 | | 股 | | | 持股比例 | 34.21% | | | | | 剩余被质押/冻结/标记股份数量 | 14,210,000 | | | 股 | 证券代码：603087 证券简称：甘李药业 公告编号：2025-028 甘李药业股份有限公司 关于公司控股股东及实际控制人部分股份解押 的公告 三、控股股东质押事项对公司的影响 公司控股股东及实际控制人甘忠如先生资信状况良好，具备相应的资金偿还 能力，其所质押的股份目前不存在平仓风险或被强 ...

Core Points - Gannee Pharmaceutical recently disclosed a significant change in shareholder equity, with Beijing Xute Hongda Technology Co., Ltd. reducing its stake in the company [1][2] - The equity change period was from April 22, 2025, to April 24, 2025, during which Xute Hongda reduced its holdings by 849,822 shares, representing 0.14% of Gannee's total share capital [1][2] - After the change, Xute Hongda holds 40,634,035 shares, accounting for 6.76% of Gannee's total share capital, while its concerted actor, Gan Zhongru, holds 205,643,757 shares, representing 34.21% [1][2] Company Information - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, while Xute Hongda is the second largest shareholder [2] - Gan Zhongru has been the controlling shareholder and actual controller of Gannee since 2020, serving as the chairman of the company [2] - Gannee Pharmaceutical was listed on the Shanghai Stock Exchange on June 29, 2020, with an initial public offering (IPO) of 40.2 million shares at a price of 63.32 yuan per share [2][3] Fundraising Activities - Gannee Pharmaceutical raised a total of 2.545 billion yuan through its IPO, with a net amount of 2.441 billion yuan after expenses [2][3] - The funds raised were intended for various projects, including marketing network construction and the registration of insulin products in the U.S. [2] - In 2023, Gannee issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [3]

Core Viewpoint - The equity change by a major shareholder of Ganli Pharmaceutical Co., Ltd. does not lead to a change in the controlling shareholder or actual controller of the company [2][6]. Group 1: Equity Change Details - After the equity change, Beijing Xutong Hongda Technology Co., Ltd. holds 40,634,035 shares, accounting for 6.76% of the total share capital [2]. - The associated party, Mr. Gan Zhongru, holds 205,643,757 shares, representing 34.21% of the total share capital, bringing the total combined holdings to 246,277,792 shares, or 40.97% of the total [2][3]. - Prior to the change, Xutong Hongda held 41,483,857 shares, which was 6.90% of the total share capital, and the combined holdings were 247,127,614 shares, or 41.11% [3]. Group 2: Compliance and Impact - The equity change complies with relevant laws and regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [3][5]. - The equity change is a normal reduction by the shareholder and will not significantly impact the company's governance structure or ongoing operations [6]. - The shares involved in this equity change all enjoy voting rights without any restrictions on transfer or delegation [4][6].

证券代码：603087 证券简称：甘李药业 公告编号：2025-027 甘李药业股份有限公司 关于持股 5%以上股东权益变动达 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次权益变动基本情况 重要内容提示： 1 本次权益变动后不会使甘李药业股份有限公司（以下简称"公司"）控 股股东及实际控制人发生变化。 本次权益变动属于北京旭特宏达科技有限公司（以下简称"旭特宏达"） 按照计划实施减持导致，不触及要约收购，不会导致公司控股股东及实 际控制人发生变化。本次权益变动后，信息披露义务人旭特宏达持有公 司无限售条件流通股 40,634,035 股，占公司总股本的 6.76%；其一致行 动人甘忠如先生持有公司股份 205,643,757 股，占公司总股本的 34.21%， 二者合计持有公司股份 246,277,792 股，占公司总股本的 40.97%。 注：1、表格中数据尾差是由于四舍五入造成。 2、本次权益变动前，信息披露义务人旭特宏达持有公司无限售条件流通股 41,483,857 股，占公司总股本的 6. ...

重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人（会计主管人员）周丽保证季度报告中 财务信息的真实、准确、完整。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603087 证券简称：甘李药业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 √适用 □不 ...